Posted on: 11/22/2006

J Neurooncol. 2006 Oct 4; [Epub ahead of print] Related Articles, Links

 
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.

Chamberlain MC, Chalmers L.

Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Avenue, Tampa, FL, 33612-0804, USA, ChambeMC@moffitt.usf.edu.

There is no standard of care for elderly patients (age >/= 70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4-14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.

PMID: 17019532 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!